{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:19:44Z","timestamp":1780679984059,"version":"3.54.1"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Insulinomas are predominantly benign neuroendocrine tumors originating from beta cells within the islets of Langerhans of the endocrine pancreas. Because surgical resection represents the only curative therapy option, exact tumor localization and discrimination of insulinomas from focal or diffuse manifestations of congenital hyperinsulinism are crucial for optimal treatment strategies. We investigated the diagnostic value of glucagon-like peptide 1 receptor PET\/CT using <jats:sup>68<\/jats:sup>Ga-DOTA-exendin 4 for detecting insulinomas and compared the diagnostic value of PET scans performed at 2 time points.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In 10 patients with clinically and biochemically suspected insulinoma, PET\/CT was performed at 1 hour (PET1) and 2 hours (PET2) after injection of <jats:sup>68<\/jats:sup>Ga-DOTA-exendin 4. In this retrospective analysis, tracer uptake was visually assessed in both scans by 2 independent readers. SUVmax and tumor-to-background ratio (TBR) of focal lesions were assessed. Imaging results were compared with histopathologic findings, if patients underwent resection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Increased focal <jats:sup>68<\/jats:sup>Ga-DOTA-exendin 4 uptake was observed in 8 of 10 patients concordantly by both readers. Seven patients with focal uptake underwent surgery with tumor enucleation and histopathologic proof of insulinoma (7\/8). Two of 10 patients without focal uptake were considered to suffer from diffuse form of congenital hyperinsulinism and consequently received medical treatment. A significant increase of tumoral SUVmax on PET2 (PET1: SUVmax 20.2 \u00b1 8.2 g\/mL; PET2: SUVmax 24.7 \u00b1 7.9 g\/mL; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0018) did not result in a significant improvement in TBR (PET1: TBR 4.9 \u00b1 1.7; PET2: TBR 4.3 \u00b1 1.2; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.2892).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Focal uptake of <jats:sup>68<\/jats:sup>Ga-DOTA-exendin 4 reliably indicated insulinomas as histopathologically confirmed in all patients undergoing consecutive surgery. The diagnostic value of PET2 was not found to be superior to PET1, indicating that a single 1-hour <jats:sup>68<\/jats:sup>Ga-DOTA-exendin 4 PET\/CT scan is a sufficient and convenient approach for patient care.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000003093","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T03:57:39Z","timestamp":1590465459000},"page":"519-524","source":"Crossref","is-referenced-by-count":20,"title":["Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET\/CT"],"prefix":"10.1097","volume":"45","author":[{"given":"Kerstin","family":"Michalski","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Laubner","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetology, Department of Medicine II, Faculty of Medicine, Medical Center\u2013University of Freiburg, University of Freiburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Stoykow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Aymen","family":"Omrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut R.","family":"Maecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Seufert","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetology, Department of Medicine II, Faculty of Medicine, Medical Center\u2013University of Freiburg, University of Freiburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Goetz","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp T.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juri","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0025-6196(12)62083-7","article-title":"Functioning insulinoma\u2014incidence, recurrence, and long-term survival of patients: a 60-year study","volume":"66","year":"1991","journal-title":"Mayo Clin Proc"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/bjs.5280","article-title":"The management of insulinoma","volume":"93","year":"2006","journal-title":"Br J Surg"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/MPA.0000000000000110","article-title":"A systematic review of localization, surgical treatment options, and outcome of insulinoma","volume":"43","year":"2014","journal-title":"Pancreas"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.bpg.2005.05.008","article-title":"Insulinoma","volume":"19","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1210\/jc.2011-0164","article-title":"Nesidioblastosis no longer! It\u2019s all about genetics","volume":"96","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3748\/wjg.v19.i6.829","article-title":"Diagnosis and management of insulinoma","volume":"19","year":"2013","journal-title":"World J Gastroenterol"},{"key":"bib7-20230925","first-page":"274","article-title":"Evaluation of endocrine tests. D: the prolonged fasting test for insulinoma","volume":"67","year":"2009","journal-title":"Neth J Med"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00423-011-0801-z","article-title":"Enucleation in pancreatic surgery: indications, technique, and outcome compared to standard pancreatic resections","volume":"396","year":"2011","journal-title":"Langenbecks Arch Surg"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0002-9610(80)90427-4","article-title":"Insulinoma in Seattle: 39 cases in 30 years","volume":"140","year":"1980","journal-title":"Am J Surg"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ssu.2980060208","article-title":"Endocrine neoplasms (non-gastrin) of the pancreas","volume":"6","year":"1990","journal-title":"Semin Surg Oncol"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/BF01655841","article-title":"The ultrasonic detection of insulinomas during surgical exploration of the pancreas","volume":"11","year":"1987","journal-title":"World J Surg"},{"key":"bib12-20230925","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/01.RVI.0000140638.55375.1E","article-title":"Selective arterial calcium stimulation and hepatic venous sampling in the evaluation of hyperinsulinemic hypoglycemia: potential and limitations","volume":"15","year":"2004","journal-title":"J Vasc Interv Radiol"},{"key":"bib13-20230925","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(13)70049-4","article-title":"Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study","volume":"1","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"bib14-20230925","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMc0802045","article-title":"Glucagon-like peptide 1-receptor scans to localize occult insulinomas","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"bib15-20230925","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00259-012-2299-1","article-title":"Glucagon-like peptide-1 receptor imaging with Lys40(Ahx-HYNIC- 99mTc\/EDDA)NH2-exendin-4 for the detection of insulinoma","volume":"40","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib16-20230925","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1007\/s00259-018-4101-5","article-title":"Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET\/CT, SPECT\/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study","volume":"45","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib17-20230925","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2967\/jnumed.115.167445","article-title":"Glucagon-like peptide-1 receptor PET\/CT with 68Ga-NOTA-exendin-4 for detecting localized Insulinoma: a prospective cohort study","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib18-20230925","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/10606820213687","article-title":"Structure-function of the glucagon receptor family of G protein\u2013coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors","volume":"8","year":"2002","journal-title":"Recept Channels"},{"key":"bib19-20230925","doi-asserted-by":"crossref","first-page":"10S","DOI":"10.2967\/jnumed.116.186882","article-title":"Approaches to multireceptor targeting: hybrid radioligands, radioligand cocktails, and sequential radioligand applications","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib20-20230925","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2967\/jnumed.106.038679","article-title":"GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting","volume":"48","year":"2007","journal-title":"J Nucl Med"},{"key":"bib21-20230925","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00259-003-1184-3","article-title":"Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting","volume":"30","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib22-20230925","doi-asserted-by":"crossref","first-page":"e0160714","DOI":"10.1371\/journal.pone.0160714","article-title":"99mTc Labeled glucagon-like peptide-1-analogue (99mTc-GLP1) scintigraphy in the management of patients with occult insulinoma","volume":"11","year":"2016","journal-title":"PLoS ONE"},{"key":"bib23-20230925","first-page":"561","article-title":"99mTc labeled GLP-1 scintigraphy with the use of [Lys40-(Ahx-HYNIC\/EDDA)NH2]-exendin-4 in the insulinoma localization","volume":"52","year":"2011","journal-title":"J Nucl Med"},{"key":"bib24-20230925","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7150\/thno.38366","article-title":"Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics","volume":"10","year":"2020","journal-title":"Theranostics"},{"key":"bib25-20230925","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7150\/thno.4024","article-title":"Radiolabeled peptides: valuable tools for the detection and treatment of cancer","volume":"2","year":"2012","journal-title":"Theranostics"},{"key":"bib26-20230925","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1210\/jc.2008-1410","article-title":"Evaluation and management of adult hypoglycemic disorders: an Endocrine Society clinical practice guideline","volume":"94","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"bib28-20230925","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","year":"2020","journal-title":"Histopathology"},{"key":"bib29-20230925","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00259-014-2943-z","article-title":"18F-FDOPA PET\/CT imaging of insulinoma revisited","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib30-20230925","first-page":"353","article-title":"Clinical value of 18F-FDOPA PET\/CT with contrast enhancement and without carbidopa premedication in patients with insulinoma","volume":"38","year":"2018","journal-title":"Anticancer Res"},{"key":"bib31-20230925","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1210\/jc.2016-3445","article-title":"Localization of insulinoma using 68Ga-DOTATATE PET\/CT scan","volume":"102","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"bib32-20230925","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00259-016-3331-7","article-title":"Role of (68)Ga somatostatin receptor PET\/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib33-20230925","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ccr3.1448","article-title":"Diagnostic challenges in a patient with an occult insulinoma: 68Ga-DOTA-exendin-4 PET\/CT and 68Ga-DOTATATE PET\/CT","volume":"6","year":"2018","journal-title":"Clin Case Rep"},{"key":"bib34-20230925","doi-asserted-by":"crossref","first-page":"R203","DOI":"10.1530\/ERC-17-0005","article-title":"Molecular imaging in the investigation of hypoglycaemic syndromes and their management","volume":"24","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"bib35-20230925","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2967\/jnumed.110.085142","article-title":"Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas","volume":"52","year":"2011","journal-title":"J Nucl Med"},{"key":"bib36-20230925","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2967\/jnumed.111.087999","article-title":"PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference","volume":"52","year":"2011","journal-title":"J Nucl Med"},{"key":"bib37-20230925","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1210\/jc.2009-1082","article-title":"Glucagon-like peptide-1 receptor imaging for localization of insulinomas","volume":"94","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"bib38-20230925","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1097\/RLU.0000000000002522","article-title":"Volume replacement fluid demarks benign insulinoma with 68Ga-DOTA-exendin-4 PET\/CT","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib39-20230925","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1021\/acs.molpharmaceut.9b00271","article-title":"Exendin-4 derivatives with an albumin-binding moiety show decreased renal retention and improved GLP-1 receptor targeting","volume":"16","year":"2019","journal-title":"Mol Pharm"},{"key":"bib40-20230925","doi-asserted-by":"crossref","first-page":"e0170435","DOI":"10.1371\/journal.pone.0170435","article-title":"Radioiodinated exendin-4 is superior to the radiometal-labelled glucagon-like peptide-1 receptor probes overcoming their high kidney uptake","volume":"12","year":"2017","journal-title":"PLoS One"},{"key":"bib41-20230925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41181-017-0036-6","article-title":"Radiosynthesis and evaluation of an 18F-labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma","volume":"3","year":"2018","journal-title":"EJNMMI Radiopharm Chem"},{"key":"bib42-20230925","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s12020-015-0633-7","article-title":"Preoperative localization of adult nesidioblastosis using 68Ga-DOTA-exendin-4-PET\/CT","volume":"50","year":"2015","journal-title":"Endocrine"},{"key":"bib43-20230925","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2967\/jnumed.119.228627","article-title":"PET-based human dosimetry of 68Ga-NODAGA-exendin 4, a tracer for \u03b2-cell imaging","volume":"61","year":"2020","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:09:41Z","timestamp":1695622181000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003093","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,22]]}}}